PubMed Health⌕ Search

Biomedical subjects

J Pichl

Publications and source records attributed to J Pichl.

26 records · Page 2Linked to original sources
PubMed1985

[Therapeutic pancreatic duct occlusion in chronic pancreatitis: clinical, exocrine and endocrine consequences in a 12 month follow-up study].

Therapeutic pancreatic duct occlusion (PDO) is applied to preserve endocrine pancreatic function by atrophizing and thus eliminating chronically inflamed exocrine pancreatic parenchyma. So far, efficient and lasting elimination of exocrine parenchyma is brought about only by intraoperative PDO upon partial duodenopancreatectomy. While partial duodenopancreatectomy itself reduces endocrine pancreatic function by about 40%, intraoperative PDO does not further impair endocrine function. Endocrine function is not affected at all by endoscopic PDO, which has to be improved, however, concerning its eliminatory effect on exocrine pancreatic parenchyma.

Blood Glucose↗
PubMed1985

Beta-cell reserve capacity in chronic pancreatitis.

The degree of correlation between exocrine pancreatic function and endocrine secretory capacity was examined in 13 chronic pancreatitis patients with secondary diabetes mellitus, 8 chronic pancreatitis patients without diabetes, and 11 healthy subjects. The two parameters were studied under maximal stimulation (volume-corrected secretin-pancreozym test and glucose-tolbutamide-glucagon provocation, respectively). A close, linear correlation was found between all endocrine variables and pancreatic acinar function (e.g. rs = 0.77 for chymotrypsin output and C-peptide release; p less than 0.0001). The correlation was less strong with pancreatic bicarbonate output (e.g. rs = 0.49 for C-peptide release; p less than 0.05). In our patients, secondary overt diabetes occurred in chronic pancreatitis when protease outputs were, on an average, reduced to about 10% of the mean maximal protease output of normal subjects.

Adult↗
PubMed1984

[Results of scintigraphic studies with 131I-meta-benzylguanidine in space-occupying lesions of neuroectodermal origin].

Between 1982 and 1984, 48 studies with 131I-meta-benzylguanidine were carried out in Erlangen in patients with suspected pheochromocytoma or neuroblastoma. Scintigraphy with MIBG was found to be highly specific. False positive findings can be avoided if with weak uptakes an exact correlation with the results of morphological studies such as CT or sonography is sought and if follow-up observations ensure that they are not caused by activity residues in the biliary, intestinal or urinary pathways. False negative findings are made in 5-10% of the investigations in pheochromocytoma and in 41% of those in neuroblastoma patients. In pheochromocytoma the uptake rates are generally low (1-2%), whereas in neuroblastoma they may reach 10% and more.

3-Iodobenzylguanidine↗
PubMed1982

Splenic abscess-clinical symptoms and diagnostic possibilities.

A 71-yr-old female patient was admitted for investigation of a massive leukocytosis and loss of weight. Physical examination revealed a reduction in the respiratory excursion of the left lung, a left pleural friction rub located ventrobasally and tension of the upper abdominal wall. Additional diagnostic procedure excluded extrasplenic disease. Ultrasound-guided puncture demonstrated the presence of pus in the splenic bed, and splenic abscess was diagnosed. Subsequent surgery confirmed this diagnosis. Histological findings revealed extensive splenic infarction. Since bacteriological investigation revealed the identical pathogens in the pus obtained with the puncture needle, in the intraoperative swab and in the midstream urine, the splenic abscess was most likely caused by hematogenous spread of a urinary tract infection into the splenic infarction. The postoperative course was uneventful, and the patient was discharged on the 11th postoperative day, free of symptoms. The clinical picture, radiological diagnosis, origin, therapy and course of splenic abscess are discussed with reference to the literature.

Abscess↗
PubMed1978

Lysine acetylisalicylate inhibits the protein synthesis in the rat gastric mucosa in vivo and in vitro.

Lysine acetylsalicylate (LAS), a water soluble derivative of acetylsalicylic acid and parenterally administrable analgesic, locally inhibits the incorporation of 14C protein hydrolysate into proteins of the rat isolated gastric mucosa. A similar effect on protein synthesis was observed after s.c. administration of the drug, whereas DNA and RNA synthesis were not affected. Obviously, LAS inhibits the translation step during biosynthesis of proteins. It is conceivable that this effect contributes to the potential ulcerogenic action of acetylsalicylate and that parenteral administration is not a criteria to protect the stomach from salicylate-induced side effects.

Animals↗